Interestingly, the previously described VEGFR-3 inhibitor, SAR131675, reduces the number of circulating MDSCs, increases the proportion of tumor associated “M1-like” macrophages and reduces tumor growth and metastasis. This evidence concerns the gene FLT4 and neoplasm.